FUKUDA DENSHI (6960) FY2026 Q3 Earnings Report

Quick View

Executive Summary

The most important point this fiscal period is that the Company is in a “decreased revenue and decreased profit” phase, rather than a “increased revenue and decreased profit” phase, as higher SG&A expenses pressured earnings despite largely flat revenue. Revenue was ¥98.86B (down -0.5% YoY), Operating Income was ¥16.40B (down -5.7%), Ordinary Income was ¥16.76B (down -6.8%), and Net Income was ¥11.73B (compared with ¥12.37B in the previous year). Although the gross profit margin improved to 53.8% from 52.6% in the previous year, the SG&A ratio rose to 37.2% from 35.1%, causing the Operating Income margin to decline to 16.6% from 17.5%.

Factors Affecting Earnings

【Revenue】Revenue was ¥98.86B, essentially flat, down 0.5% YoY. By segment, Medical Treatment Equipment accounted for the largest share at ¥47.08B, with a profit margin of 18.7%, the highest among all segments. Consumables and Other (¥29.06B, profit margin 14.5%), Physiological Testing Equipment (¥16.83B, profit margin 14.4%), and Patient Monitoring Equipment (¥5.88B, profit margin 16.6%) followed. Cost of sales decreased 3.1% YoY, while gross profit increased to ¥53.22B (up +1.8%), improving the gross profit margin to 53.8%.

【Profit and Loss】Despite the improvement in the gross profit margin, SG&A expenses increased to ¥36.82B (up +5.7% YoY), outpacing the decline in revenue, and Operating Income decreased to ¥16.40B (down -5.7%). Non-operating income and expenses deteriorated from the previous year, resulting in net non-operating income of ¥0.36B, and Ordinary Income declined further to ¥16.76B (down -6.8%). Extraordinary income and expenses were small at a net ¥0.075B, limiting their impact on results. Net Income was ¥11.73B (compared with ¥12.37B in the previous year), with income taxes and other taxes of ¥5.11B recorded against Profit Before Tax of ¥16.84B. In conclusion, the current period saw decreased revenue and decreased profit.

Segment Analysis

The Medical Treatment Equipment segment is the core business, with revenue of ¥47.08B accounting for 47.6% of total revenue, and is the most profitable segment with a profit margin of 18.7%. The Consumables and Other segment (¥29.06B, profit margin 14.5%) provides a stable earnings base, while Physiological Testing Equipment (¥16.83B, profit margin 14.4%) has a relatively low profit margin. Patient Monitoring Equipment (¥5.88B), although small in scale, performed solidly with a profit margin of 16.6%. Against the Company-wide Operating Income margin of 16.6%, the 18.7% margin of Medical Treatment Equipment drives overall profitability, meaning that demand trends in this segment have a significant impact on overall performance.

Key Financial Indicators

【Profitability】The Operating Income margin of 16.6% and Net Income margin of 11.9% are both high, but declined from 17.5% and 12.5%, respectively, in the previous-year period. The structure is clear: the improvement in the gross profit margin (53.8%, compared with 52.6% in the previous year) was offset by higher SG&A expenses (37.2%, compared with 35.1% in the previous year). 【Cash Quality】The ¥5.03B difference between Ordinary Income of ¥16.76B and Net Income of ¥11.73B was primarily attributable to income taxes and other taxes of ¥5.11B. The impact of temporary factors was small, with net extraordinary income and expenses of ¥0.075B, and earnings quality is supported by recurring revenue generation. 【Investment Efficiency】ROE (annualized) of 8.6% reflects the Company’s substantial equity base and low leverage, indicating room for improvement in capital efficiency relative to its high profitability. BPS was ¥6,648.60, up from ¥6,301.01 in the previous year. 【Financial Soundness】With an Equity Ratio of 84.1% and cash and deposits of ¥63.28B against interest-bearing debt consisting solely of short-term borrowings of ¥1.80B, the financial foundation is extremely strong.

Cash Flow Analysis

Although the disclosed items in the statement of cash flows are limited, cash trends can be inferred from changes in the balance sheet. Cash and deposits were ¥63.28B, down ¥9.09B from ¥72.37B in the previous year. The acquisition of treasury shares (¥37.19B, an increase of ¥9.93B YoY) and additional investments in investment securities (¥19.88B, up 34.8% YoY) represented significant uses of funds. Current assets were ¥115.02B and current liabilities were ¥29.66B, resulting in a high current ratio of approximately 388%, with no concerns regarding short-term liquidity. Property, plant and equipment was ¥61.11B, up from ¥56.41B in the previous year, suggesting that capital investment is continuing. Overall, the Company appears to be pursuing conservative cash management, allocating cash generated from operating activities to shareholder returns and asset investment.

Earnings Quality

Current-period earnings were centered on revenue generated from recurring business activities, with limited impact from extraordinary income and expenses. Extraordinary income of ¥0.10B (including gains on the sale of fixed assets) and extraordinary losses of ¥0.02B (including impairment losses) were each less than 1% of Net Income, indicating limited dependence on temporary factors. Non-operating income of ¥0.51B consisted primarily of dividend income of ¥0.24B, representing only 0.5% of revenue. Profit creation from the core business supports overall earnings. Meanwhile, comprehensive income was ¥15.04B, exceeding Net Income of ¥11.73B by ¥3.31B, primarily due to a ¥3.35B increase in valuation difference on other securities. The fact that valuation gains on investment securities boosted comprehensive income represents a valuation element sensitive to market fluctuations and must be understood separately from recurring cash-generating capacity.

Earnings Forecast and Guidance

The full-year Company forecast calls for Revenue of ¥137.00B (down -1.4% YoY), Operating Income of ¥24.00B (down -7.2%), and Ordinary Income of ¥24.00B (down -9.9%), indicating that the Company itself expects decreased revenue and decreased profit. The Q3 cumulative progress rates were 72.2% for Revenue, 68.3% for Operating Income, and 69.8% for Ordinary Income, slightly below the standard 75% progress level. To achieve the full-year forecast, approximately ¥7.60B in Operating Income and an Operating Income margin of approximately 19.9% will be required in the remaining quarter, above the Q3 cumulative Operating Income margin of 16.6%. Continued improvement in the gross profit margin and control of the pace of SG&A growth will be key to achieving the full-year targets.

Shareholder Returns

The full-year dividend forecast is ¥180.00 per share (interim dividend of ¥90.00), implying a forecast Payout Ratio of approximately 29.1% against forecast EPS of ¥617.78. This Payout Ratio represents dividends alone as a percentage of Net Income and is distinct from the Total Return Ratio, which includes treasury share repurchases. Treasury share purchases increased by ¥9.93B from ¥27.26B in the previous year to ¥37.19B, indicating that shareholder returns are being advanced through treasury share repurchases in addition to dividends. Given the net cash position of cash and deposits of ¥63.28B and interest-bearing debt of ¥1.80B, there appears to be ample capacity to sustain the dividend.

Risk Factors

1. Deterioration in inventory efficiency: Product inventories were ¥11.83B, up 24.4% YoY. Building up inventories while revenue remains sluggish could pressure profit margins through inventory write-downs or discount sales if demand recovery is delayed.

2. Declining ability to absorb SG&A expenses: SG&A expenses were ¥36.82B, up 5.7% YoY, significantly exceeding the ¥0.95B increase in gross profit. This deterioration in cost absorption was the primary cause of the decline in Operating Income, making a review of the cost structure a key focus going forward.

3. Refinancing structure considerations: Interest-bearing debt of ¥1.80B consists entirely of short-term borrowings, resulting in a short-term debt ratio of 100%. However, cash and deposits exceed interest-bearing debt by more than 35 times, suggesting that the actual liquidity risk is limited.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the Operating Income margin and Net Income margin are substantially above the industry median, placing the Company’s profitability among the higher levels within the industry.

Growth and Capital Efficiency

The Revenue growth rate is below the industry median, indicating relative underperformance in top-line growth.

※Source: Compiled by the Company

Key Points from the Financial Results

1. The gross profit margin improved to 53.8% from the previous year, but higher SG&A expenses (up +5.7% YoY) offset this improvement, causing the Operating Income margin to decline to 16.6%. A notable feature in assessing earnings quality is that changes in the cost structure affected performance more than revenue trends.

2. Achieving the full-year forecast requires a recovery of the Operating Income margin to approximately 19.9% in the remaining quarter, making the gap with the Q3 cumulative result of 16.6% a key point for future monitoring.

3. Against the backdrop of a strong financial foundation, including an Equity Ratio of 84.1% and cash and deposits of ¥63.28B, shareholder returns through treasury share repurchases (up +¥9.93B YoY) have been strengthened. At the same time, the 24.4% increase in product inventories should continue to be monitored for consistency with demand trends.

Theoretical Share Price (Reference Value)

Sensitivity: ¥6,332–¥6,698 at ±1% for the cost of equity, and ¥6,506–¥6,514 at ±0.1 for ω.

Notes:

• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest-rate reference month: 2026-07 / Mechanically calculated using only publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional as necessary.

---End of Report---